545 related articles for article (PubMed ID: 26092297)
1. Droxidopa in neurogenic orthostatic hypotension.
Kaufmann H; Norcliffe-Kaufmann L; Palma JA
Expert Rev Cardiovasc Ther; 2015; 13(8):875-91. PubMed ID: 26092297
[TBL] [Abstract][Full Text] [Related]
2. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience.
Mathias CJ
Clin Auton Res; 2008 Mar; 18 Suppl 1():25-9. PubMed ID: 18368304
[TBL] [Abstract][Full Text] [Related]
3. Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases.
Pérez-Lloret S; Quarracino C; Otero-Losada M; Rascol O
Expert Opin Pharmacother; 2019 Apr; 20(6):635-645. PubMed ID: 30730771
[TBL] [Abstract][Full Text] [Related]
4. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
Kaufmann H; Saadia D; Voustianiouk A; Goldstein DS; Holmes C; Yahr MD; Nardin R; Freeman R
Circulation; 2003 Aug; 108(6):724-8. PubMed ID: 12885750
[TBL] [Abstract][Full Text] [Related]
5. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
Mathias CJ; Senard JM; Braune S; Watson L; Aragishi A; Keeling JE; Taylor MD
Clin Auton Res; 2001 Aug; 11(4):235-42. PubMed ID: 11710796
[TBL] [Abstract][Full Text] [Related]
6. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.
Isaacson SH; Skettini J
Vasc Health Risk Manag; 2014; 10():169-76. PubMed ID: 24729712
[TBL] [Abstract][Full Text] [Related]
7. Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.
Keating GM
Drugs; 2015 Feb; 75(2):197-206. PubMed ID: 25559422
[TBL] [Abstract][Full Text] [Related]
8. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.
Kaufmann H
Clin Auton Res; 2008 Mar; 18 Suppl 1():19-24. PubMed ID: 18368303
[TBL] [Abstract][Full Text] [Related]
9. New developments in the management of neurogenic orthostatic hypotension.
Biaggioni I
Curr Cardiol Rep; 2014 Nov; 16(11):542. PubMed ID: 25303896
[TBL] [Abstract][Full Text] [Related]
10. Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303).
Isaacson S; Shill HA; Vernino S; Ziemann A; Rowse GJ
J Parkinsons Dis; 2016 Oct; 6(4):751-759. PubMed ID: 27636856
[TBL] [Abstract][Full Text] [Related]
11. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
Kaufmann H; Freeman R; Biaggioni I; Low P; Pedder S; Hewitt LA; Mauney J; Feirtag M; Mathias CJ;
Neurology; 2014 Jul; 83(4):328-35. PubMed ID: 24944260
[TBL] [Abstract][Full Text] [Related]
12. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
Biaggioni I; Freeman R; Mathias CJ; Low P; Hewitt LA; Kaufmann H;
Hypertension; 2015 Jan; 65(1):101-7. PubMed ID: 25350981
[TBL] [Abstract][Full Text] [Related]
13. Diagnosing and treating neurogenic orthostatic hypotension in primary care.
Kuritzky L; Espay AJ; Gelblum J; Payne R; Dietrich E
Postgrad Med; 2015; 127(7):702-15. PubMed ID: 26012731
[TBL] [Abstract][Full Text] [Related]
14. Neurogenic orthostatic hypotension: roles of norepinephrine deficiency in its causes, its treatment, and future research directions.
Loavenbruck A; Sandroni P
Curr Med Res Opin; 2015 Nov; 31(11):2095-104. PubMed ID: 26373628
[TBL] [Abstract][Full Text] [Related]
15. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension.
Biaggioni I; Arthur Hewitt L; Rowse GJ; Kaufmann H
BMC Neurol; 2017 May; 17(1):90. PubMed ID: 28494751
[TBL] [Abstract][Full Text] [Related]
16. Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
François C; Rowse GJ; Hewitt LA; Vo P; Hauser RA
BMC Neurol; 2016 Aug; 16(1):143. PubMed ID: 27538531
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
Isaacson S; Vernino S; Ziemann A; Rowse GJ; Kalu U; White WB
J Am Soc Hypertens; 2016 Oct; 10(10):755-762. PubMed ID: 27614923
[TBL] [Abstract][Full Text] [Related]
18. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension.
Palma JA; Norcliffe-Kaufmann L; Martinez J; Kaufmann H
Neurology; 2018 Oct; 91(16):e1539-e1544. PubMed ID: 30232253
[TBL] [Abstract][Full Text] [Related]
19. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
Hauser RA; Isaacson S; Lisk JP; Hewitt LA; Rowse G
Mov Disord; 2015 Apr; 30(5):646-54. PubMed ID: 25487613
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension.
Elgebaly A; Abdelazeim B; Mattar O; Gadelkarim M; Salah R; Negida A
Clin Auton Res; 2016 Jun; 26(3):171-80. PubMed ID: 26951135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
